Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12112246 | 0.92 | PIK3CD (0.37) | PIK3CD | |
| SCHEMBL12112236 | 0.89 | PIK3CD (0.47) | PIK3CDADORA2AADORA1HPGDTSHR | |
| SCHEMBL16123777 | 0.88 | PIK3CD (0.41) | PIK3CDADORA2AADORA1HPGDTSHR | |
| SCHEMBL13394115 | 0.88 | PIK3CD (0.41) | PIK3CDADORA2AADORA1HPGDTSHR | |
| SCHEMBL12112237 | 0.87 | PDE4A (0.42) | PIK3CDADORA2AADORA1HPGDTSHR | |
| SCHEMBL12112243 | 0.86 | PIK3CD (0.40) | PIK3CDADORA2AADORA1HPGDTSHR | |
| SCHEMBL15214193 | 0.86 | SLC29A1 (0.46) | PIK3CDADORA2AADORA1HPGDTSHR | |
| SCHEMBL12112232 | 0.79 | PIK3CD (0.39) | PIK3CDADORA2A | |
| SCHEMBL12112250 | 0.79 | PIK3CD (0.37) | PIK3CDADORA2A | |
| SCHEMBL12112229 | 0.79 | SLC29A1 (0.43) | PIK3CDADORA2AHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9322831-B2 | DDX3 as a biomarker for cancer and methods related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | PIK3CD 2000/4885ADORA2A 4578/4885ADORA1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.